Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03 ...

Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and ...

Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands ...

This renewed interest in DB presented Tarsus with an opportunity to reup its efforts to combat a pressing yet often overlooked health condition.

On Wednesday, Oppenheimer updated its outlook on Tarsus Pharmaceuticals (NASDAQ:TARS), a $1.8 billion market cap biotechnology company, increasing the price target to $72.00 from the previous $65. ...

Allspring Global Investments Holdings LLC cut its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) ...

Consider a fitting Easter follow up story. Lord George Lyttleton (1709-1773) was a graduate of Oxford University, a prolific poet, and member of British Parliament. He and his equally esteemed ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) in ...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...